The Commission amended the information regarding SmPCs, dosage adjustments, Posology and method of administration, and therapeutic indication for Aranesp. The CHMP granted positive opinions for all centrally-authorized erythropoiesis stimulating agents (ESAs) in the EU, each of which will receive European Commission decisions.